| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCTD |
| Uniprot No | P32321 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-178aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSEVSCKKRDDYLEWPEYFMAVAFLSAQRS KDPNSQVGACIVNSENKIVGIGYNGMPNGCSDDVLPWRRTAENKLDTKYP YVCHAELNAIMNKNSTDVKGCSMYVALFPCNECAKLIIQAGIKEVIFMSD KYHDSDEATAARLLFNMAGVTFRKFIPKCSKIVIDFDSINSRPSQKLQ |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCTD重组蛋白的模拟参考文献示例(内容为虚构，仅供格式参考)：
1. **名称**: "Cloning and High-level Expression of Recombinant DCTD in Escherichia coli"
**作者**: Zhang L., et al.
**摘要**: 本研究成功将人源DCTD基因克隆至pET载体，并在大肠杆菌BL21中实现可溶性表达。通过优化诱导条件(如IPTG浓度和温度)，获得高纯度重组蛋白，经SDS-PAGE和Western blot验证，为后续功能研究奠定基础。
2. **名称**: "Structural Characterization of DCTD Recombinant Protein by X-ray Crystallography"
**作者**: Smith J.R., et al.
**摘要**: 报道了DCTD重组蛋白的晶体结构解析(分辨率2.1Å)，揭示其催化活性中心的关键氨基酸残基。该结构为理解DCTD在核苷酸代谢中的作用机制及药物靶点设计提供依据。
3. **名称**: "Functional Analysis of Recombinant DCTD in Pyrimidine Salvage Pathway"
**作者**: Tanaka K., et al.
**摘要**: 通过体外酶活实验证实，纯化的DCTD重组蛋白可将脱氧胞苷单磷酸(dCMP)转化为脱氧尿苷单磷酸(dUMP)，且活性受ATP浓度调控，提示其在DNA修复中的潜在作用。
4. **名称**: "Development of a Mammalian Cell-based DCTD Expression System for Therapeutic Applications"
**作者**: Chen H., et al.
**摘要**: 利用CHO细胞表达具有糖基化修饰的DCTD重组蛋白，证明其血清稳定性较原核表达产物显著提升。体外实验显示该蛋白可有效恢复DCTD缺陷型细胞的代谢功能，提示基因治疗应用潜力。
注：以上文献为示例性内容，实际研究中请通过学术数据库检索真实文献。
**Background of DCTD Recombinant Protein**
DCTD (Deoxycytidylate Deaminase) is a critical enzyme involved in nucleotide metabolism, specifically catalyzing the deamination of deoxycytidine monophosphate (dCMP) to deoxyuridine monophosphate (dUMP). This reaction is essential for maintaining balanced dTTP pools required for DNA synthesis and repair. Dysregulation of DCTD activity has been implicated in genomic instability, cancer progression, and resistance to anticancer therapies, particularly antimetabolites like gemcitabine.
Recombinant DCTD protein is engineered using genetic cloning techniques, where the *DCTD* gene is expressed in heterologous systems such as *E. coli* or mammalian cell lines. This approach ensures high purity, scalability, and the ability to introduce specific mutations for functional studies. The recombinant protein retains enzymatic activity, enabling researchers to study its kinetic properties, substrate specificity, and interactions with inhibitors or regulatory molecules.
In biomedical research, DCTD recombinant protein serves as a vital tool for **1)** elucidating mechanisms of nucleotide metabolism in health and disease, **2)** screening potential therapeutic agents targeting DCTD in cancers, and **3)** understanding resistance mechanisms to nucleoside analog drugs. Structural studies using X-ray crystallography or cryo-EM further reveal conformational changes during catalysis, guiding rational drug design.
Recent studies highlight DCTD's dual role as a metabolic enzyme and a potential biomarker, with overexpression observed in certain tumors. Its recombinant form accelerates translational research, bridging gaps between basic enzymology and clinical applications in precision oncology.
×
